We audited the diagnostic accuracy of ROTEM® (TEM Innovations, GmbH, Munich, Germany) measurements of hypofibrinogenaemia (fibrinogen <1.5 g/l) and thrombocytopenia (platelet count <100 x 10 9 /l) in 200 adult non-transplant patients during cardiopulmonary bypass (CPB). Blood samples were obtained for FIBTEM (assay for the fibrin part of the clot), PLTEM (calculated platelet-specific component), and laboratory measurements simultaneously. Our thresholds for FIBTEM and PLTEM were A10 (clot firmness 10 minutes after clotting time) ≤8 mm, and <35 mm respectively. We also calculated the accuracy of smaller thresholds and earlier indices. We found that FIBTEM A10 ≤8 mm had low sensitivity (0.62) for hypofibrinogenaemia. With the 13% hypofibrinogenaemia prevalence in our sample, the positive predictive value (PPV) was 0.47. In contrast, FIBTEM A10 ≤8 mm had higher specificity (0.90) (negative predictive value [NPV] 0.94). Of the other FIBTEM values analysed, only A5 ≤6 mm had similar or superior accuracy. The PLTEM results were less encouraging (sensitivity 0.81, specificity 0.62). With our prevalence of thrombocytopenia (also 13%), the PPV was only 0.24. However, the NPV was high (0.96). Of the other PLTEM values analysed, only A5 <25 mm had similar or superior accuracy. These findings indicate that during CPB FIBTEM A10 ≤8 mm and PLTEM A10 <35 mm have greater accuracy in identifying the absence of hypofibrinogenaemia and thrombocytopenia respectively than their presence. On the basis of these results we would be reassured by FIBTEM A10 values >8 mm and PLTEM A10 values ≥35 mm, but would continue to use laboratory measurements for confirmation. We would not use FIBTEM A10 ≤8 mm or PLTEM A10 <35 mm values alone to guide replacement therapy unless clinical conditions warranted an immediate decision before laboratory measurements were available.
. Like many cardiac surgical centres worldwide, we have used rotational thromboelastometry to guide coagulation factor replacement in cardiac surgical patients for many years. This was initially to supplement rather than replace the information provided by laboratory coagulation measurements. However, due to the rapid availability of ROTEM results (typically <15 minutes), there has been an increasing tendency to rely on ROTEM measurements alone, rather than to wait for confirmation through laboratory values (typically >30 minutes). It has also become more common to perform the ROTEM measurements prior to separation from cardiopulmonary bypass (CPB) (i.e. in the presence of heparin), to allow planning of coagulation management if bleeding occurs in the early post-CPB period. In order to assess the validity of this practice, we audited the diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) of ROTEM measurements obtained prior to separation from CPB using laboratory measurements as a reference standard. Our focus was on the identification of hypofibrinogenaemia and thrombocytopenia, being the two most common coagulation disturbances requiring correction in the presence of abnormal bleeding in cardiac surgical patients [1] [2] [3] .
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Methods
The audit was performed at the Sir Charles Gairdner Hospital, Nedlands (SCGH), Western Australia, and the St John of God Hospital, Subiaco (SJOGHS), Western Australia. The audit was registered as a quality assurance project at both sites (SCGH quality activity 25029; SJOGHS quality activity 1383). Data from all patients who had simultaneous ROTEM and laboratory coagulation measurements performed prior to the separation from CPB from both sites were included. The use of both ROTEM and laboratory measurements to assess coagulation prior to separation from CPB was based on anaesthetists' individual practices. The audit was retrospective with no patients having additional ROTEM or laboratory coagulation monitoring or altered management in anticipation of the audit being performed.
Anaesthetic management was at the discretion of the supervising anaesthetist. The (porcine) heparin dose prior to CPB was 300 IU/kg with further doses of 5,000-10,000 IU given incrementally as necessary to maintain the kaolin activated clotting time >480 seconds. The CPB circuit was an Affinity Fusion™ Oxygenator with a Carmeda® bioactive surface (Medtronic, Minneapolis, MN, USA) primed with 2 litres Plasma-Lyte (Baxter Healthcare Corporation, Deerfield, IL, USA) crystalloid and 10,000 IU heparin. The management of CPB included mild hypothermia (32°C-35°C) with a target mean arterial pressure of 50-80 mmHg and a pump flow of 2.4 l/min/m 2 . Myocardial protection was achieved with a combination of antegrade and retrograde intermittent blood cardioplegia or antegrade crystalloid cardioplegia (Custodiol®, Bensheim, Germany) depending on surgical procedure and surgeon preference. The use of tranexamic acid (15 mg/kg pre-CPB followed by up to 4.5 mg/ kg/hour during CPB) was dependent on surgical procedure and surgeon preference.
Blood samples were taken from the CPB circuit during the rewarming phase when the patient's nasopharyngeal temperature reached 35°C. After discarding 2 ml dead space, the blood was transferred into two 2.7 ml citrated blood collection tubes (Vacutainer, Becton Dickinson and Company, Franklin Lakes, NJ, USA) and one 2.7 ml EDTA tube (K2 ethylene-diamine-tetra-acetic acid). All three tubes were transported within five minutes to the pathology laboratory. The fibrinogen concentration was estimated using the Clauss method 4 and the platelet count was measured using a ROCHE haematology analyser (Sysmex XN, Milton Keynes, UK). The ROTEM assays (ROTEM ® Delta, TEM Innovations, GmbH, Munich, Germany) were performed in the same laboratory following preheating of blood samples to 37°C. For the EXTEM analysis (which screens for the extrinsic haemostatic system), 20 µl star-tem® (0.2 mol/l CaCl 2 ) and 20 µl of EXTEM activator (containing recombinant tissue factor, phospholipids, polybrene heparin inhibitor, preservatives and buffer) was added to a 300 µl aliquot of citrated blood 5, 6 . For the FIBTEM analysis (assay for the fibrin component of the clot) this was repeated with the addition of 20 µl cytochalasin D (to inhibit platelets and thereby provide an index of fibrinogen contribution to the EXTEM independent of platelets) 5, 6 . The automated sequence allows the test cup (with blood and reagents) to engage the pin and start the test. There is an automatic calculation and digital display of ROTEM variables including EXTEM and FIBTEM amplitudes at five and ten minutes after commencement of clotting (A5 and A10). The PLTEM (platelet contribution to EXTEM) was derived by subtracting the FIBTEM from the corresponding EXTEM 7, 8 . Regular quality controls were performed as per manufacturer recommendations.
We calculated the sensitivity (probability of a positive result given the presence of the target condition) and specificity (probability of a negative result given the absence of the target condition) of ROTEM assessments of hypofibrinogenaemia (FIBTEM A10 ≤8 mm) and thrombocytopenia (PLTEM A10 <35 mm) using laboratory measurements of fibrinogen (<1.5 g/l) and platelet count (<100 x 10 9 /l) as reference standards. The laboratory thresholds were based on the recommended triggers for fibrinogen and platelet transfusion in the presence of diffuse bleeding in published reviews and guidelines [1] [2] [3] [9] [10] [11] . The ROTEM thresholds were based on the equivalent FIBTEM and PLTEM triggers recommended in previous studies [5] [6] [7] [8] . In addition, as there has been interest in using even earlier ROTEM values (i.e. A5) and smaller thresholds (e.g. ≤6 mm for FIBTEM, <25 mm for PLTEM) [5] [6] [7] [8] , we included an analysis of the diagnostic accuracy of these alternative ROTEM results. However, as this study was an audit of our practice, rather than an investigation of the value of ROTEM measurements per se, we did not perform any further analysis or calculate receiver-operator characteristics.
For all chosen thresholds we calculated the positive and negative predictive values (PPV, probability of presence of the target condition given a positive result; NPV, probability of absence of the target condition given a negative result). To obtain 95% confidence intervals (CI) ≤ ±5% absolute, assuming a sensitivity or specificity of about 0.83 (as has been previously reported) [5] [6] [7] [8] , at least 200 patients would be required 12 . Therefore we recruited this number of eligible patients. With this number, the widest 95% CI (i.e. that would occur with a sensitivity or specificity = 0.5) would be ≤ ±7% absolute 12 . These 95% CI estimates would also apply to all other results reported as proportions 12 . For the data analysis, missing data were assumed to be above the thresholds for hypofibrinogenaemia or thrombocytopenia for both laboratory and ROTEM indices, and to be missing completely at random. Data were rounded to two decimal places (≥0.005 rounded up, <0.005 rounded down).
Results
Simultaneous (commenced within 5 minutes of collection) ROTEM and laboratory coagulation measurements were performed in 200 consecutive patients across the two sites over a ten-month period (May 2017 to March 2018). This represented 53% of the total of 374 patients who required CPB for their cardiac surgical procedure across both sites over this period. The remaining patients either had no simultaneous ROTEM and laboratory coagulation measurements performed, or had these performed post-CPB. Summary demographic and procedural data on the 200 included patients are presented in Table 1 . All were adult (>18 years) and none were receiving transplants (not performed at either institution). Data were obtained from all patients for both ROTEM and laboratory values. Only 12 of the 1,200 values were missing (FIBTEM A10 1, FIBTEM A5 3, PLTEM A10 0, PLTEM A5 1, laboratory fibrinogen 2, laboratory platelet count 5).
The prevalence of hypofibrinogenaemia (laboratory fibrinogen <1.5 g/l) was 13%. The prevalence of thrombocytopenia (laboratory platelet count <100 x 10 9 /l) was also 13%. The similarity in these percentages was coincidental as only seven of the 200 patients developed both hypofibrinogenaemia and thrombocytopenia. The FIBTEM data are shown in Table 2 . The PLTEM data are shown in Table 3 . The individual 2 x 2 tables for the eight ROTEM parameters are included in the Appendix.
Discussion
Our results indicate that our use of ROTEM measurements during CPB has low sensitivity for the detection of hypofibrinogenaemia. For example, the FIBTEM A10 ≤8 mm value had a sensitivity of only 0.62. In contrast, FIBTEM A10 ≤8 mm had a high specificity (0.90) for the detection of hypofibrinogenaemia. These results should be interpreted in the light of the prevalence of hypofibrinogenaemia in our sample, because while sensitivity and specificity are independent of the prevalence of a condition, PPVs and NPVs are not 13 . With our prevalence of 13%, the PPV of a FIBTEM A10 value ≤8 mm was 0.47 ( Table 2 ), indicating that 53% of such values would be false positive. In contrast, the NPV was 0.94 ( Table 2 ), indicating that only 6% of FIBTEM A10 values >8 mm would be false negative. These findings indicate that with a hypofibrinogenaemia prevalence of 13%, FIBTEM A10 ≤8 mm has greater accuracy in identifying the absence of this level of hypofibrinogenaemia than its presence.
Of the other three FIBTEM values analysed, only the A5 ≤6 mm had similar or superior diagnostic accuracy to the A10 ≤8 mm. The sensitivity was slightly lower (0.58), but the specificity was slightly higher (0.95) ( Table 2 ). This was associated with a higher PPV (0.65) with no decrease in NPV (0.94). In contrast, the A10 ≤6 mm had a much lower sensitivity (0.31), and although the sensitivity of the A5 ≤8 mm was higher at 0.77, this was associated with a specificity decrease to 0.81.
The results for identification of thrombocytopenia were less encouraging (Table 3) . While the sensitivity of PLTEM /l). N=200. A10, A5: clot firmness (in mm) 10 minutes and 5 minutes respectively after clotting time. Of the other PLTEM values analysed, only the A5 <25 mm had diagnostic accuracy approaching that of the A10 <35 mm. The sensitivity of the PLTEM A5 <25 mm was slightly lower (0.73), but the specificity was slightly higher (0.71) ( Table 3) . These values were associated with a similar PPV (0.28) and NPV (0.95). The PLTEM A10 <25 mm had a sensitivity of only 0.19, and while the A5 <35 mm had a sensitivity of 1.0, its specificity was only 0.13.
For screening purposes, a test with high sensitivity is required for a negative result to reliably rule out a target condition, while high specificity is required for a positive result to reliably rule in the condition 13 . Using sensitivities and specificities alone, our results would be unreliable for either ruling in or ruling out either hypofibrinogenaemia or thrombocytopenia. Taking prevalence into account, our PPVs were also low (≤0.65) for both hypofibrinogenaemia and thrombocytopenia (Tables 2 and 3 ). In contrast, our NPVs were consistently high (≥0.89) for both hypofibrinogenaemia and thrombocytopenia (Tables 2 and 3) .
Our findings for fibrinogen were similar to those reported by Mace et al in a large sample of cardiac surgical patients during CPB Their results differed from our A5 results, in that they found a high sensitivity for all three thresholds of fibrinogen (1.0, 1.0, 0.94 respectively), with lower specificities (0.42, 0.53, 0.91). Their PPV for fibrinogen <1.5 g/l of 0.53 was also higher than our finding of 0.38 (although we used A5 ≤8 mm not ≤9.5 mm). However, our NPVs were similar (1.0 versus 0.96). Olde Engberink et al also investigated the diagnostic accuracy of PLTEM values for the detection of thrombocytopenia with the same threshold as our study (platelet count <100 x 10 9 /l), but using a slightly different A5 threshold (<22 mm versus <25 mm). With this threshold their sensitivity was 0.66 with a specificity of 0.97. This differed from our findings (A5 <25 mm sensitivity 0.73, specificity 0.71). Unfortunately, unlike the Mace et al study, our findings are not directly comparable to those of Olde Engberink et al, because only 38 of their samples were taken during CPB; 84% of their samples were taken after transfusion of one or more blood products; and 43 of their samples were repeats from the same patients. Their prevalence of hypofibrinogenaemia <1.5 g/l and thrombocytopenia <100 x 10 9 /l was also higher (27% and 33% respectively). The latter may reflect their selective use of ROTEM measurements for high-risk patients only.
Ji et al investigated the ability of ROTEM measurements (n=98) during CPB to predict hypofibrinogenaemia and thrombocytopenia post-CPB 8 . They found that a FIBTEM A10 ≤8 mm value had a sensitivity of 0.62 and a specificity of 0.88 to predict fibrinogen <1.5 g/l (n=62), and a PLTEM ≤33 mm value had a sensitivity of 0.84 and a specificity of 0.71 to predict a platelet count <100 x 10 9 /l (n=98). Our findings were similar to those of Ji et al for both hypofibrinogenaemia and thrombocytopenia.
In another study by Erdoes et al, 110 high-risk cardiac surgical patients had paired FIBTEM and laboratory fibrinogen levels measured during CPB 14 . The authors reported that the sensitivity and specificity of the FIBTEM A10 for a concurrent fibrinogen level <1.6 g/l were balanced best at an A10 cut-off of 7.5 mm (sensitivity 0.89, specificity 0.88). When repeated post-CPB, the mean values of both FIBTEM and laboratory fibrinogen levels did not change significantly, although both had low precision. The accuracy during CPB of FIBTEM A10 ≤7 mm for prediction of post-CPB fibrinogen level <1.5 g/l was 0.87 for both sensitivity and specificity. It is not possible to compare our findings directly due to the different thresholds used.
There have been several other clinical agreement studies reporting correlation coefficients or bias and precision of ROTEM versus laboratory values in cardiac surgical patients 15, 16, 18 . However, correlation coefficients may be misleading, because high correlations can occur despite large differences 19, 20 . Bias and precision provide useful summary information, but may not help when a yes/no decision has to be made in a particular patient.
There are two potential confounding factors that must be considered when measuring fibrinogen levels during CPB. Firstly, the reference fibrinogen may be affected by the high levels of heparin required to maintain anticoagulation (typically 2-4 IU/ml) 21, 22 . However, the studies by Erdoes et al and Ogawa et al both reported little change in fibrinogen level pre-and post-CPB, suggesting little if any effect of the heparin present 14, 17 . In our audit, the fibrinogen level measured during CPB had a mean value of 2.1 g/l, which would make significant artefactual reductions by heparin unlikely. Nevertheless, an effect of heparin in a proportion of our patients cannot be excluded. In contrast, ROTEM measurements are not affected by heparin (up to 5 IU/ml) due to the addition of polybrene 3, 5 . Laboratory fibrinogen measurements are also influenced by the haemoglobin (Hb) level 23 , but this effect occurs only with high Hb levels, with little change in the range of Hb levels typical during and immediately after CPB 23 . In order to avoid selection bias in diagnostic accuracy studies, patient recruitment should ideally be random or consecutive 24 . In our audit, consecutive patients who had simultaneous ROTEM and laboratory measurements performed during CPB were included, but only 53% of the patients had simultaneous measurements. Nevertheless, the final sample included a typical case-mix of cardiac surgical patients (Table 1) , and the prevalence of both hypofibrinogenaemia and thrombocytopenia were within the ranges reported in previous studies [6] [7] [8] . Our sample size was also such that our 95% CI were relatively small, and we had very few missing values. It is likely that our findings would apply to other groups of similar cardiac surgical patients, with the important caveat that prevalence must be considered when considering PPVs and NPVs. Our findings also apply only to measurements during CPB and to the particular thresholds we used for hypofibrinogenaemia and thrombocytopenia.
Another form of potential bias in diagnostic accuracy tests occurs if the results of the index test are known to those performing and interpreting the reference tests or vice versa, because prior knowledge may inadvertently bias the performance or interpretation of the tests 25, 26 . In our audit, both the index tests and reference tests were performed at the same time in the same laboratory, in many cases by the same personnel. Nevertheless, both tests provide automated results requiring little interpretation, making the absence of blinding less of a concern than if subjective interpretation was required.
Ideally, target outcomes in diagnostic accuracy studies should be based on clinical endpoints rather than reference standards 26 . For cardiac surgery the clinical endpoint of excessive bleeding is influenced by many factors independent of coagulation. Moreover, coagulation itself is complex with no global indices capable of assessing all the components that contribute to or inhibit clot formation. Several studies have investigated the effect of using ROTEM indices on clinical endpoints such as blood loss, blood transfusion, and bleeding complications (or a combination) during and after major surgery, and these have been subject to systematic reviews [27] [28] [29] . Most of these reviews have shown a benefit of using ROTEM measurements. However, in none of the studies has it been possible to exclude bias. For this reason, while many professional bodies and organisations recommend the use of viscoelastic measurements during major procedures associated with extensive blood loss, the level of recommendation is typically B or C [27] [28] [29] . Under these circumstances, studies assessing the ability of ROTEM indices to identify particular coagulation defects, rather than outcome per se, may increase the confidence with which clinical decisions are made 30 . Nevertheless, our study was an audit, not a prospective investigation, and this limitation should be considered when interpreting the results.
In summary, on the basis of the results of our audit we would be reassured by FIBTEM A10 values >8 mm and PLTEM A10 values ≥35 mm during CPB due to their high NPV for fibrinogen <1.5 g/l and platelet count <100 x 10 9 /l respectively, but we would continue to use laboratory measurements for confirmation. In contrast, we would not rely on positive FIBTEM (A10 ≤8 mm) or PLTEM (A10 <35 mm) findings to guide administration of fibrinogen or platelet replacement therapy, unless clinical conditions were such that an immediate decision was required before laboratory measurements were available. In all cases we would use ROTEM measurements to assist but not to govern clinical decision-making. Overall, we would be more confident with FIBTEM than with PLTEM values. It is possible that A5 values with a smaller threshold (FIBTEM ≤6 mm, PLTEM <25 mm) provide similar diagnostic accuracy to our original A10 thresholds (FIBTEM ≤8 mm, PLTEM <35 mm) and could be used if even earlier decisions were required in more urgent circumstances.
Appendix 
